Skip to main content
Caplight Logo









XWPharma

XWPharma

Private
Redwood City, CaliforniaHealthcare & Life Scienceshttps://www.xwpharma.com/

Last Round

Series C

Sep 17, 2020

Total Funding Raised

$63M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

XWPharma is a biotechnology company that develops innovative therapeutics to address sleep, neuropsychological, and other neglected central nervous system disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Mental Health

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug discoverysmall-molecule therapeuticsneurological disordersclinical-stage biotechdrug licensingcontract research organizationCROpharmacokineticsCNS drug developmentbiotech pipelinedrug developmentbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

XWPharma Comparables

Compare XWPharma with similar companies based on industry and business-model similarity.

XWPharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CuraSen Therapeutics, Inc.
77%
Avadel Pharmaceuticals PLC
75%
Sage Therapeutics
74%

XWPharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CSep 17, 2020
Series BSep 20, 2017
Series ASep 1, 2014

XWPharma Investors

Notable investors and investment history

XWPharma investors
InvestorRounds
Kleiner Perkins ChinaSeries A
WI Harper GroupSeries C, Series B
Orient Hontai CapitalSeries C
KTB VenturesSeries B, Series C
SANY GroupSeries C
Daol InvestmentSeries B, Series C
Kleiner PerkinsSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Grew 37% QoQ, from 19 to 26 employees.

  • Apr 18, 2026

    Grew 35% QoQ, from 17 to 23 employees.

XWPharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

XWPharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about XWPharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersRedwood City, California
Employee Range27
Year Founded2014
Last FundingSep 17, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?